Patents by Inventor Antje Gasparic

Antje Gasparic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of Treating Obesity and Metabolic Disorders
    Publication number: 20090143392
    Abstract: The invention relates to methods of treating or preventing obesity, type 2 diabetes, metabolic syndrome, or glucose intolerance using pyrido[3,2-e]pyrazines which are inhibitors of PDE10. The invention further relates to methods of reducing body fat or body weight.
    Type: Application
    Filed: November 25, 2008
    Publication date: June 4, 2009
    Applicant: ELBION GMBH
    Inventors: Norbert Hofgen, Hans Stange, Barbara Langen, Ute Egerland, Rudolf Schindler, Antje Gasparic, Chris Rundfeldt, Thomas Pfeifer
  • Novel hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for preparing them
    Publication number: 20070093531
    Abstract: The invention relates to substituted 4- or/and 7-hydroxyindoles, to processes for preparing them, to pharmaceutical preparations which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 4, as active compounds for treating diseases which can be influenced by using the compounds according to the invention to inhibit phosphodiesterase 4 activity in immunocompetent cells (e.g. macrophages and lympho-cytes).
    Type: Application
    Filed: November 30, 2006
    Publication date: April 26, 2007
    Inventors: Norbert Hofgen, Hildegard Kuss, Ute Egerland, Chris Rundfeldt, Helge Hartenhauer, Antje Gasparic
  • Hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for preparing them
    Patent number: 7166637
    Abstract: The invention relates to substituted 4- or/and 7-hydroxyindoles, to processes for preparing them, to pharmaceutical preparations which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 4, as active compounds for treating diseases which can be influenced by using the compounds according to the invention to inhibit phosphodiesterase 4 activity in immunocompetent cells (e.g. macrophages and lymphocytes).
    Type: Grant
    Filed: November 13, 2003
    Date of Patent: January 23, 2007
    Assignee: Elbion AG
    Inventors: Norbert Höfgen, Hildegard Kuss, Ute Egerland, Chris Rundfeldt, Helge Hartenhauer, Antje Gasparic
  • Novel hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for preparing them
    Publication number: 20040147759
    Abstract: The invention relates to substituted 4- or/and 7-hydroxyindoles, to processes for preparing them, to pharmaceutical preparations which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 4, as active compounds for treating diseases which can be influenced by using the compounds according to the invention to inhibit phosphodiesterase 4 activity in immunocompetent cells (e.g. macrophages and lymphocytes).
    Type: Application
    Filed: November 13, 2003
    Publication date: July 29, 2004
    Inventors: Norbert Hofgen, Hildegard Kuss, Ute Egerland, Chris Rundfeldt, Helge Hartenhauer, Antje Gasparic
  • 2,5-Dihydro-pyrazolo[3,4-d]pyrimidin-4-ones with an anticonsulsive action and methods for producing the same
    Publication number: 20030186997
    Abstract: The invention relates to 2,5-dihydropyrazolo[3,4-d]pyrimidin-4-ones and their tautomers which contain in the 5-position an ar(alkyl) radical and in the 2-position a hydrogen or an ar(alkyl) radical, processes for their preparation and their use as medicaments, in particular for the treatment of epilepsy of various forms.
    Type: Application
    Filed: February 18, 2003
    Publication date: October 2, 2003
    Inventors: Thomas Arnold, Hans-Joachim Lankau, Klaus Unverferth, Christine Tober, Chris Rundfeldt, Rita Dost, Katrin Bernoster, Antje Gasparic